https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52045 Wed 27 Sep 2023 10:07:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42906 Wed 07 Sep 2022 15:50:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52000 Tue 26 Sep 2023 11:29:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50033 T among the Finnish cancer patients and subsequently genotyped the mutation in additional breast cancer cases (n = 5259) and population controls (n = 3586) from Finland and Belarus. No significant association with breast cancer risk was seen in the meta-analysis of the Finnish datasets or in the large BCAC dataset. The association with previously identified risk variants rs999737, rs2588809, and rs1314913 was replicated among all breast cancer cases and also among familial cases in the BCAC dataset. The most significant association was observed for the haplotype carrying the risk-alleles of all the three SNPs both among all cases (odds ratio (OR): 1.15, 95% confidence interval (CI): 1.11-1.19, P = 8.88 x 10-16) and among familial cases (OR: 1.24, 95% CI: 1.16-1.32, P = 6.19 x 10-11), compared to the haplotype with the respective protective alleles. Our results suggest that loss-of-function mutations in RAD51B are rare, but common variation at the RAD51B region is significantly associated with familial breast cancer risk.]]> Thu 29 Jun 2023 13:56:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45124 Thu 27 Oct 2022 10:53:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47275 Mon 27 Mar 2023 13:35:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47334 Fri 13 Jan 2023 11:55:34 AEDT ]]>